Literature DB >> 16052575

Is periodontal disease mediated by salivary BAFF in Sjögren's syndrome?

Jacques-Olivier Pers1, Frédérique d'Arbonneau, Valérie Devauchelle-Pensec, Alain Saraux, Yvon-Louis Pennec, Pierre Youinou.   

Abstract

OBJECTIVE: To correlate the periodontal status of 15 patients with primary Sjögren's syndrome (SS) with their salivary levels of BAFF.
METHODS: The periodontal status of 15 patients who fulfilled the criteria for primary SS was compared with that of 15 controls with xerostomia who did not fulfill the criteria for primary SS but had similar symptoms of dry mouth. The level of BAFF was measured in paired samples of saliva and serum using in-house enzyme-linked immunosorbent assays. Periodontitis was assessed by the plaque index, the modified gingival index, the papillary bleeding index, and the periodontal pocket depth.
RESULTS: Notwithstanding the better oral hygiene practices of the patients with primary SS compared with those of the xerostomia controls and the subsequent reduction of their plaque index scores, complications of periodontitis, such as bleeding, gingival hypertrophy, and periodontal pockets, were not improved. This failure to ameliorate the complications of periodontitis in patients with primary SS was associated with high levels of BAFF in their saliva compared with the levels in xerostomia controls (7.4 +/- 2.1 versus 1.0 +/- 0.4 ng/ml [P < 0.002]). The levels of BAFF in saliva did not correlate with the levels in sera but did correlate with the periodontal pocket depth (P < 0.002).
CONCLUSION: These findings are similar to the bone resorption observed in patients with rheumatoid arthritis. They suggest that the known effect of B cells in periodontitis would be partly mediated by salivary BAFF in patients with primary SS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16052575     DOI: 10.1002/art.21205

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  12 in total

1.  Polymicrobial infection alter inflammatory microRNA in rat salivary glands during periodontal disease.

Authors:  Gautam Nayar; Adrienne Gauna; Sasanka Chukkapalli; Irina Velsko; Lakshmyya Kesavalu; Seunghee Cha
Journal:  Anaerobe       Date:  2015-10-22       Impact factor: 3.331

Review 2.  A conspicuous role for B cells In Sjögren's syndrome.

Authors:  Pierre Youinou; Valérie Devauchelle; Pascal Hutin; Rozenn Le Berre; Alain Saraux; Jacques-Olivier Pers
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

3.  Periodontal disease in rheumatoid arthritis and Sjogren's syndrome: a modifiable risk factor for atherosclerosis?

Authors:  Satish Rachapalli
Journal:  Rheumatol Int       Date:  2008-09-20       Impact factor: 2.631

Review 4.  Sjögren's syndrome in older patients: aetiology, diagnosis and management.

Authors:  Rada V Moerman; Hendrika Bootsma; Frans G M Kroese; Arjan Vissink
Journal:  Drugs Aging       Date:  2013-03       Impact factor: 3.923

Review 5.  Disturbance of cytokine networks in Sjögren's syndrome.

Authors:  Pierre Youinou; Jacques-Olivier Pers
Journal:  Arthritis Res Ther       Date:  2011-07-06       Impact factor: 5.156

6.  Periodontitis in patients with cirrhosis: a cross-sectional study.

Authors:  Lea Ladegaard Grønkjær; Palle Holmstrup; Søren Schou; Johanne Kongstad; Peter Jepsen; Hendrik Vilstrup
Journal:  BMC Oral Health       Date:  2018-02-13       Impact factor: 2.757

7.  Acquisition of N-Glycosylation Sites in Immunoglobulin Heavy Chain Genes During Local Expansion in Parotid Salivary Glands of Primary Sjögren Patients.

Authors:  Annie Visser; Marieke E Doorenspleet; Niek de Vries; Fred K L Spijkervet; Arjan Vissink; Richard J Bende; Hendrika Bootsma; Frans G M Kroese; Nicolaas A Bos
Journal:  Front Immunol       Date:  2018-03-12       Impact factor: 7.561

8.  Patients with chronic periodontitis present increased risk for primary Sjögren syndrome: a nationwide population-based cohort study.

Authors:  Tai-Chen Lin; Chien-Fang Tseng; Yu-Hsun Wang; Hui-Chieh Yu; Yu-Chao Chang
Journal:  PeerJ       Date:  2018-06-20       Impact factor: 2.984

Review 9.  The future of biologic agents in the treatment of Sjögren's syndrome.

Authors:  Jiska M Meijer; Justin Pijpe; Hendrika Bootsma; Arjan Vissink; Cees G M Kallenberg
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

10.  Persistence and selection of an expanded B-cell clone in the setting of rituximab therapy for Sjögren's syndrome.

Authors:  Uri Hershberg; Wenzhao Meng; Bochao Zhang; Nancy Haff; E William St Clair; Philip L Cohen; Patrice D McNair; Ling Li; Marc C Levesque; Eline T Luning Prak
Journal:  Arthritis Res Ther       Date:  2014-02-11       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.